

LITERATÚRA

1. Brod SA. Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. *Mult Scler Relat Disord.* 2020;46:102538.
2. Costello F, Burton JM. Contemporary management challenges in seropositive NMOSD. *J Neurol.* 2022;1-8.
3. Cree BA, Lamb S, Morgan K, Chen A, et al. An open label study of the effects of rituximab in neuromyelitis optica. *Neurology.* 2005; 64:1270-1272.
4. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. *The Lancet.* 2019;394:1352-1363.
5. Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. *JAMA Neurol.* 2016;73:1342-1348.
6. Giovannelli J, Ciron J, Cohen M, et al. A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica. *Ann Clin Transl Neurol.* 2021;8:2025-2037.
7. Kim W and Kim HJ. An update on biologic treatments for neuromyelitis optica spectrum disorder. *Expert Rev Clin Immunol.* 2023;19(1):111-121.
8. Kümpfel T, Gíglhuber K, Aktas O, et al. The Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. *Journal of Neurology.* 2023;271(1):141-176.
9. Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. *Ann Neurol.* 2016;79:206-216.
10. Li R, Li C, Huang Q, et al. Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation. *Eur J Neurol.* 2022;29:2792-2800.
11. Lin J, Xue B, Zhu R, et al. Intravenous immunoglobulin as the rescue treatment in NMOSD patients. *Neurol Sci.* 2021;42:3857-3863.
12. Nakashima I, Nakahara J, Yokote H, et al. Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan. *Ther Adv Neurol Disord.* 2023;16:1-13.
13. Palace J, Wingerchuk DM, Fujihara K, et al. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial. *Mult Scler Relat Disord.* 2021;47:102641.
14. Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. *Ann Neurol.* 2023;93:1053-1068.
15. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. *N Engl J Med.* 2019;381:614-625.
16. Rensel M, Zabeti A, Mealy MA, et al. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ≥ 4 years in the N-MOmentum trial. *Mult Scler (Houndmills, Basingstoke, Engl).* 2022;28:925-932.
17. Ringelstein M.ECTRIMS 2022 – ePoster. *Mult Scler J.* 2022;28:692-945.
18. Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. *JAMA Neurol.* 2015;72:756-763.
19. Siritho S, Nopsopon T, Pongpirul K. Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis. *J Neurol.* 2021;268:4549-4562.
20. Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet Neurol.* 2020;19:298-306.
21. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. *Lancet Neurol.* 2020;19:402-412.
22. Valencia-Sanchez C, Wingerchuk DM. Emerging targeted therapies for Neuromyelitis Optica Spectrum Disorders. *BioDrugs.* 2021;35:7-17.
23. Wang Y, Zhong X, Wang H, et al. Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks. *Eur J Neurol.* 2022;30:195-203.
24. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology.* 2015;85:177-189.
25. Wingerchuk DM, Fujihara K, Palace J, et al. Long-term safety and efficacy of eculizumab in aquaporin-4 IgG positive NMOSD. *Ann Neurol.* 2021;89:1088-1098.
26. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. *N Engl J Med.* 2019;381:2114-2124.
27. Yamamura T, Weinschenker B, Yeaman MR, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAKuraSky and SAKuraStar. *Mult Scler Relat Disord.* 2022;66:104025.
28. Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. *Lancet Neurol.* 2020;19:391-401.

ON-LINE KURZ

Našli jsme vzácného pacienta – hledejme dál



OBSAH KURZU

- ▶ Úvod do lyzosomálních střádavých onemocnění
doc. RNDr. MUDr. Pavel Ješina, Ph.D.
- ▶ Niemann-Pickova choroba typu B – nové léčitelné onemocnění
doc. RNDr. MUDr. Pavel Ješina, Ph.D.
- ▶ Gaucherova nemoc – snadno diagnostikovatelné onemocnění
MUDr. Stella Reichmannová, Ph.D.
- ▶ Pompeho nemoc – jak odhalit typické i méně typické případy
MUDr. Lívie Mensová
- ▶ Diskuze

ODBOBNÝ GARANT:

doc. RNDr. MUDr. Pavel Ješina, Ph.D.

POŘADATEL:

Společnost SOLEN, s. r. o.,
ve spolupráci s Klinikou pediatrie a dědičných poruch metabolismu 1. LF UK a VFN v PrazePOČET
KREDITŮ **2**Registrace
ZDARMATERMÍN
květen 2024
až duben 2025
dostupný na
online.solen.czZLATÝ
PARTNER

